Cargando…
Ten-year survival outcome of breast cancer patients in India
INTRODUCTION: Breast cancer is the most frequently diagnosed cancer among women in India; however, there are no studies addressing long-term survival (10 years and above). This study sought to evaluate long-term oncological outcome among women with breast cancer treated with a curative intent. MATER...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202444/ https://www.ncbi.nlm.nih.gov/pubmed/34211337 http://dx.doi.org/10.4103/jcar.JCar_26_20 |
_version_ | 1783707984484892672 |
---|---|
author | Viral, Patel Pavithran, K. Beena, K. Shaji, Ajil Vijaykumar, D. K. |
author_facet | Viral, Patel Pavithran, K. Beena, K. Shaji, Ajil Vijaykumar, D. K. |
author_sort | Viral, Patel |
collection | PubMed |
description | INTRODUCTION: Breast cancer is the most frequently diagnosed cancer among women in India; however, there are no studies addressing long-term survival (10 years and above). This study sought to evaluate long-term oncological outcome among women with breast cancer treated with a curative intent. MATERIALS AND METHODS: This is a retrospective cohort analysis of 1301 breast cancer patients of all stages who had received primary treatment with curative intent from 2004 to 2010 at a single cancer institution of India. RESULTS: A total of 1301 breast cancer patients were available for final analysis. The median age was 51 years (range, 21–86 years). 70.25% of the patients had early breast cancer (EBC), 21.9% had locally advanced breast cancer, and 7.85% of the patients with de novo metastatic disease also underwent surgery. 56.5% of the patients had hormone-sensitive tumors, human epidermal growth factor receptor 2 over expression was seen in 17%, and triple-negative tumors accounted for 26.2% of the patients. The 5- and 10-year overall survival (OS) of the entire cohort was 79% and 66%, and the 5- and 10-year breast cancer-specific survival (BCSS) was 79% and 70%, respectively. OS and BCSS were 51% and 58%, respectively, at 15-year follow-up after primary cancer treatment. On multivariate analysis, the factors associated with prolonged survival were age ≤50 years, EBC, and treatment during the later period (2008–2010). CONCLUSION: Difference between OS and BCSS was found to have an increasing trend during 10–15-year follow-up, the difference being 4% at 10 years and 7% at 15 years. Age ≤50 years, early-stage disease at presentation, and primary cancer treatment in later years (2008–2010) were favorable predictors for 10-year survival. |
format | Online Article Text |
id | pubmed-8202444 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-82024442021-06-30 Ten-year survival outcome of breast cancer patients in India Viral, Patel Pavithran, K. Beena, K. Shaji, Ajil Vijaykumar, D. K. J Carcinog Original Article INTRODUCTION: Breast cancer is the most frequently diagnosed cancer among women in India; however, there are no studies addressing long-term survival (10 years and above). This study sought to evaluate long-term oncological outcome among women with breast cancer treated with a curative intent. MATERIALS AND METHODS: This is a retrospective cohort analysis of 1301 breast cancer patients of all stages who had received primary treatment with curative intent from 2004 to 2010 at a single cancer institution of India. RESULTS: A total of 1301 breast cancer patients were available for final analysis. The median age was 51 years (range, 21–86 years). 70.25% of the patients had early breast cancer (EBC), 21.9% had locally advanced breast cancer, and 7.85% of the patients with de novo metastatic disease also underwent surgery. 56.5% of the patients had hormone-sensitive tumors, human epidermal growth factor receptor 2 over expression was seen in 17%, and triple-negative tumors accounted for 26.2% of the patients. The 5- and 10-year overall survival (OS) of the entire cohort was 79% and 66%, and the 5- and 10-year breast cancer-specific survival (BCSS) was 79% and 70%, respectively. OS and BCSS were 51% and 58%, respectively, at 15-year follow-up after primary cancer treatment. On multivariate analysis, the factors associated with prolonged survival were age ≤50 years, EBC, and treatment during the later period (2008–2010). CONCLUSION: Difference between OS and BCSS was found to have an increasing trend during 10–15-year follow-up, the difference being 4% at 10 years and 7% at 15 years. Age ≤50 years, early-stage disease at presentation, and primary cancer treatment in later years (2008–2010) were favorable predictors for 10-year survival. Wolters Kluwer - Medknow 2021-03-16 /pmc/articles/PMC8202444/ /pubmed/34211337 http://dx.doi.org/10.4103/jcar.JCar_26_20 Text en Copyright: © 2021 Journal of Carcinogenesis https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Viral, Patel Pavithran, K. Beena, K. Shaji, Ajil Vijaykumar, D. K. Ten-year survival outcome of breast cancer patients in India |
title | Ten-year survival outcome of breast cancer patients in India |
title_full | Ten-year survival outcome of breast cancer patients in India |
title_fullStr | Ten-year survival outcome of breast cancer patients in India |
title_full_unstemmed | Ten-year survival outcome of breast cancer patients in India |
title_short | Ten-year survival outcome of breast cancer patients in India |
title_sort | ten-year survival outcome of breast cancer patients in india |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202444/ https://www.ncbi.nlm.nih.gov/pubmed/34211337 http://dx.doi.org/10.4103/jcar.JCar_26_20 |
work_keys_str_mv | AT viralpatel tenyearsurvivaloutcomeofbreastcancerpatientsinindia AT pavithrank tenyearsurvivaloutcomeofbreastcancerpatientsinindia AT beenak tenyearsurvivaloutcomeofbreastcancerpatientsinindia AT shajiajil tenyearsurvivaloutcomeofbreastcancerpatientsinindia AT vijaykumardk tenyearsurvivaloutcomeofbreastcancerpatientsinindia |